⌘K

ARA

NYSE

American Renal Associates Holdings, Inc

SectorHealth CareIndustryMisc Health and Biotechnology ServicesIPO2016

News25/Ratings0

Latest news

25 items

1903dSEC
SEC Form 15-12B filed
15-12B - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1907dSEC
SEC Form EFFECT filed
EFFECT - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1912dSEC
SEC Form SC 13G/A filed
SC 13G/A - American Renal Associates Holdings, Inc. (0001498068) (Subject)
1912dINSIDER
SEC Form 4 filed by P L Partners Capital Centerbridge
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: W Thomas Erickson disposed to the issuer $0 worth of Common Stock (67,755 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: J Christopher Hocevar disposed to the issuer $0 worth of Common Stock (18,679 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: A Joseph Carlucci disposed to the issuer $0 worth of Common Stock (1,245,164 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: M John Jureller disposed to the issuer $0 worth of Common Stock (49,435 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: T Syed Kamal disposed to the issuer $0 worth of Common Stock (1,291,236 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: Victoria Labriola disposed to the issuer $0 worth of Common Stock (64,569 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: H Robert Fish disposed to the issuer $0 worth of Common Stock (43,205 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: E Don Williamson disposed to the issuer $0 worth of Common Stock (307,282 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dINSIDER
SEC Form 4: Michael Boxer disposed to the issuer $0 worth of Common Stock (100,468 units at $0.00), decreasing ownership by 100% to 0 units
4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
1913dSEC
SEC Form POS AM filed
POS AM - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1913dSEC
SEC Form S-8 POS filed
S-8 POS - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1913dSEC
SEC Form 25-NSE filed
25-NSE - American Renal Associates Holdings, Inc. (0001498068) (Subject)
1913dSEC
SEC Form 8-K filed
8-K - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1913dPR
American Renal Associates Completes Transaction With Innovative Renal Care, a Nautic Partners Portfolio Company
BEVERLY, Mass.--(BUSINESS WIRE)--Nautic Partners and its portfolio company, Innovative Renal Care (IRC), have completed the previously announced transaction to acquire American Renal Associates Holdings, Inc. (NYSE: ARA), effective January 25, 2021. The transaction creates a unique opportunity to shape the future of kidney care during a dynamic time of change, innovation and transformation in the industry. “As the healthcare industry continues to evolve, recent innovation throughout kidney and renal care has allowed for dramatic and exciting improvements in care delivery and patient experience,” said Nick Mendez, president and CEO of IRC. “ARA’s significant infrastructure and geo
1925dSEC
SEC Form 8-K filed
8-K - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1933dSEC
SEC Form DEFA14A filed
DEFA14A - American Renal Associates Holdings, Inc. (0001498068) (Filer)
1993dPR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – EIDX, WTRE, ARA, CIT
NEW YORK, Nov. 07, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. If you are an Eidos shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/. Watford Holdings Ltd. (NASDAQ: WT
1994dPR
Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc., BMC Stock Holdings, Inc., Callaway Golf Company, Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., Watford Holdings Ltd. and Yintech Investment Holdings Limited
NEW YORK, Nov. 6, 2020 /PRNewswire/ -- American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. BMC Stock Holdings, Inc. (NASDAQ: BMCH) - Builders FirstSource, Inc. (NASDAQ: BLDR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the
1994dPR
American Renal Associates Holdings, Inc. Announces Third Quarter 2020 Results
BEVERLY, Mass.--(BUSINESS WIRE)--American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the third quarter ended September 30, 2020. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures (See “Use of Non-GAAP Financial Measures” and the reconciliation tables further below). Third Quarter 2020 Highlights (all percentage changes compare Q3 2020 to Q3 2019 unless noted): Patient service operating revenues decreased 0.8% to $209.7 million; Net income attributable to American Renal As
2000dPR
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - EIDX, RESI, PE, ARA
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. If you are an Eidos shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/. Front Yard Residential Corporation
2001dPR
Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), and CIT Group Inc. (NYSE:CIT) and Mid-Con Energy Partners, LP (NASDAQ: MCEP)
NEW YORK, Oct. 30, 2020 (GLOBE NEWSWIRE) -- American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members